Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit.

Kopinja J, Sevilla RS, Levitan D, Dai D, Vanko A, Spooner E, Ware C, Forget R, Hu K, Kral A, Spacciapoli P, Kennan R, Jayaraman L, Pucci V, Perera S, Zhang W, Fischer C, Lam MH.

Sci Rep. 2017 Oct 23;7(1):13853. doi: 10.1038/s41598-017-14065-w.

2.
3.

Scale-Ampule Assembly to Assess Ramp Position for Airway Management.

Sinha A, Jayaraman L, Punhani D.

Anesth Analg. 2017 Jun;124(6):2087. doi: 10.1213/ANE.0000000000002119. No abstract available.

PMID:
28430690
4.

CRLX101, a Nanoparticle-Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α.

Tian X, Nguyen M, Foote HP, Caster JM, Roche KC, Peters CG, Wu P, Jayaraman L, Garmey EG, Tepper JE, Eliasof S, Wang AZ.

Cancer Res. 2017 Jan 1;77(1):112-122. doi: 10.1158/0008-5472.CAN-15-2951. Epub 2016 Oct 26. Erratum in: Cancer Res. 2017 Dec 1;77(23 ):6790-6791.

5.
6.

Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial.

Keefe SM, Hoffman-Censits J, Cohen RB, Mamtani R, Heitjan D, Eliasof S, Nixon A, Turnbull B, Garmey EG, Gunnarsson O, Waliki M, Ciconte J, Jayaraman L, Senderowicz A, Tellez AB, Hennessy M, Piscitelli A, Vaughn D, Smith A, Haas NB.

Ann Oncol. 2016 Aug;27(8):1579-85. doi: 10.1093/annonc/mdw188. Epub 2016 Jun 8.

7.

Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer.

Pham E, Yin M, Peters CG, Lee CR, Brown D, Xu P, Man S, Jayaraman L, Rohde E, Chow A, Lazarus D, Eliasof S, Foster FS, Kerbel RS.

Cancer Res. 2016 Aug 1;76(15):4493-503. doi: 10.1158/0008-5472.CAN-15-3435. Epub 2016 Jun 20.

8.

Dissecting Therapeutic Resistance to ERK Inhibition.

Jha S, Morris EJ, Hruza A, Mansueto MS, Schroeder GK, Arbanas J, McMasters D, Restaino CR, Dayananth P, Black S, Elsen NL, Mannarino A, Cooper A, Fawell S, Zawel L, Jayaraman L, Samatar AA.

Mol Cancer Ther. 2016 Apr;15(4):548-59. doi: 10.1158/1535-7163.MCT-15-0172. Epub 2016 Feb 1.

9.

Discovery of the Selective CYP17A1 Lyase Inhibitor BMS-351 for the Treatment of Prostate Cancer.

Huang A, Jayaraman L, Fura A, Vite GD, Trainor GL, Gottardis MM, Spires TE, Spires VM, Rizzo CA, Obermeier MT, Elzinga PA, Todderud G, Fan Y, Newitt JA, Beyer SM, Zhu Y, Warrack BM, Goodenough AK, Tebben AJ, Doweyko AM, Gold DL, Balog A.

ACS Med Chem Lett. 2015 Dec 2;7(1):40-5. doi: 10.1021/acsmedchemlett.5b00310. eCollection 2016 Jan 14.

10.
11.

ProSeal laryngeal mask airway improves oxygenation when used as a conduit prior to laryngoscope guided intubation in bariatric patients.

Sinha A, Jayaraman L, Punhani D, Panigrahi B.

Indian J Anaesth. 2013 Jan;57(1):25-30. doi: 10.4103/0019-5049.108557.

12.

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.

Morris EJ, Jha S, Restaino CR, Dayananth P, Zhu H, Cooper A, Carr D, Deng Y, Jin W, Black S, Long B, Liu J, Dinunzio E, Windsor W, Zhang R, Zhao S, Angagaw MH, Pinheiro EM, Desai J, Xiao L, Shipps G, Hruza A, Wang J, Kelly J, Paliwal S, Gao X, Babu BS, Zhu L, Daublain P, Zhang L, Lutterbach BA, Pelletier MR, Philippar U, Siliphaivanh P, Witter D, Kirschmeier P, Bishop WR, Hicklin D, Gilliland DG, Jayaraman L, Zawel L, Fawell S, Samatar AA.

Cancer Discov. 2013 Jul;3(7):742-50. doi: 10.1158/2159-8290.CD-13-0070. Epub 2013 Apr 24.

13.

Intramyometrial vasopressin: Anesthesiologists' nightmare.

Jayaraman L, Sinha A, Punhani D.

J Anaesthesiol Clin Pharmacol. 2013 Jan;29(1):135-6. doi: 10.4103/0970-9185.105832. No abstract available.

14.

ProSeal™ LMA increases safe apnea period in morbidly obese patients undergoing surgery under general anesthesia.

Sinha A, Jayaraman L, Punhani D.

Obes Surg. 2013 Apr;23(4):580-4. doi: 10.1007/s11695-012-0833-7.

PMID:
23361469
15.

Efficacy of ultrasound-guided transversus abdominis plane block after laparoscopic bariatric surgery: a double blind, randomized, controlled study.

Sinha A, Jayaraman L, Punhani D.

Obes Surg. 2013 Apr;23(4):548-53. doi: 10.1007/s11695-012-0819-5.

PMID:
23361468
16.

Dangerous sedation in an obese patient.

Jayaraman L, Sinha A, Punhani D, Jain N, Panigrahi B.

Indian J Anaesth. 2011 Nov;55(6):639. doi: 10.4103/0019-5049.90640. No abstract available.

17.

Liposuction: Anaesthesia challenges.

Sood J, Jayaraman L, Sethi N.

Indian J Anaesth. 2011 May;55(3):220-7. doi: 10.4103/0019-5049.82652.

18.

Anaesthesia for caesarean section in a patient with lumbar syringomyelia.

Jayaraman L, Sethi N, Sood J.

Rev Bras Anestesiol. 2011 Jul-Aug;61(4):469-73. doi: 10.1016/S0034-7094(11)70054-X. English, Multiple languages.

19.

Structural basis for CARM1 inhibition by indole and pyrazole inhibitors.

Sack JS, Thieffine S, Bandiera T, Fasolini M, Duke GJ, Jayaraman L, Kish KF, Klei HE, Purandare AV, Rosettani P, Troiani S, Xie D, Bertrand JA.

Biochem J. 2011 Jun 1;436(2):331-9. doi: 10.1042/BJ20102161.

PMID:
21410432
20.

Transient left ventricular apical ballooning post-pneumoperitoneum: Takotsubo cardiomyopathy. A case report.

Jayaraman L, Sethi N, Sharma S, Gautam N, Sahai C, Sood J.

Minerva Anestesiol. 2010 Jun;76(6):455-8. Epub 2008 Nov 6.

21.

An electrophoretic mobility shift assay for the identification and kinetic analysis of acetyl transferase inhibitors.

Fanslau C, Pedicord D, Nagulapalli S, Gray H, Pang S, Jayaraman L, Lippy J, Blat Y.

Anal Biochem. 2010 Jul 1;402(1):65-8. doi: 10.1016/j.ab.2010.03.025. Epub 2010 Mar 23.

PMID:
20338149
22.

Benzo[d]imidazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1)--Hit to Lead studies.

Wan H, Huynh T, Pang S, Geng J, Vaccaro W, Poss MA, Trainor GL, Lorenzi MV, Gottardis M, Jayaraman L, Purandare AV.

Bioorg Med Chem Lett. 2009 Sep 1;19(17):5063-6. doi: 10.1016/j.bmcl.2009.07.040. Epub 2009 Jul 10.

PMID:
19632837
23.

Optimization of pyrazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1).

Huynh T, Chen Z, Pang S, Geng J, Bandiera T, Bindi S, Vianello P, Roletto F, Thieffine S, Galvani A, Vaccaro W, Poss MA, Trainor GL, Lorenzi MV, Gottardis M, Jayaraman L, Purandare AV.

Bioorg Med Chem Lett. 2009 Jun 1;19(11):2924-7. doi: 10.1016/j.bmcl.2009.04.075. Epub 2009 Apr 22.

PMID:
19419866
24.

Prevention of propofol pain: a comparative study.

Sethi N, Jayaraman L, Sethi M, Sharma S, Sood J.

Middle East J Anaesthesiol. 2009 Feb;20(1):71-4.

PMID:
19266829
25.

Pyrazole inhibitors of coactivator associated arginine methyltransferase 1 (CARM1).

Purandare AV, Chen Z, Huynh T, Pang S, Geng J, Vaccaro W, Poss MA, Oconnell J, Nowak K, Jayaraman L.

Bioorg Med Chem Lett. 2008 Aug 1;18(15):4438-41. doi: 10.1016/j.bmcl.2008.06.026. Epub 2008 Jun 12.

PMID:
18619839
26.

A novel method of intubation in two children with Pierre Robin syndrome.

Sood J, Jayaraman L, Jain A, Gupta N, Sethi N, Kumar A.

Paediatr Anaesth. 2007 Jan;17(1):89-91. No abstract available.

PMID:
17184443
27.

Modification of the gum elastic bougie.

Jayaraman L, Sethi N, Kumar A, Sood J.

Anesth Analg. 2006 Nov;103(5):1336-7. No abstract available.

PMID:
17056991
28.

Laparoscopic approach to pheochromocytoma: is a lower intraabdominal pressure helpful?

Sood J, Jayaraman L, Kumra VP, Chowbey PK.

Anesth Analg. 2006 Feb;102(2):637-41.

PMID:
16428576
29.

Distinct oligomeric states of SMAD proteins in the transforming growth factor-beta pathway.

Jayaraman L, Massague J.

J Biol Chem. 2000 Dec 29;275(52):40710-7.

30.

Covalent and noncovalent modifiers of the p53 protein.

Jayaraman L, Prives C.

Cell Mol Life Sci. 1999 Jan;55(1):76-87. Review.

PMID:
10065153
31.

Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-beta signaling.

Shi Y, Wang YF, Jayaraman L, Yang H, Massagué J, Pavletich NP.

Cell. 1998 Sep 4;94(5):585-94.

32.

Physical and functional interaction of SMADs and p300/CBP.

Pouponnot C, Jayaraman L, Massagué J.

J Biol Chem. 1998 Sep 4;273(36):22865-8.

33.

High mobility group protein-1 (HMG-1) is a unique activator of p53.

Jayaraman L, Moorthy NC, Murthy KG, Manley JL, Bustin M, Prives C.

Genes Dev. 1998 Feb 15;12(4):462-72.

34.

p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner.

Ko LJ, Shieh SY, Chen X, Jayaraman L, Tamai K, Taya Y, Prives C, Pan ZQ.

Mol Cell Biol. 1997 Dec;17(12):7220-9.

36.

Identification of redox/repair protein Ref-1 as a potent activator of p53.

Jayaraman L, Murthy KG, Zhu C, Curran T, Xanthoudakis S, Prives C.

Genes Dev. 1997 Mar 1;11(5):558-70.

37.

Functional dissection of p53 tumor suppressor protein.

Jayaraman L, Freulich E, Prives C.

Methods Enzymol. 1997;283:245-56. No abstract available.

PMID:
9251024
38.
39.

DNA-binding properties of the p53 tumor suppressor protein.

Prives C, Bargonetti J, Farmer G, Ferrari E, Friedlander P, Wang Y, Jayaraman L, Pavletich N, Hubscher U.

Cold Spring Harb Symp Quant Biol. 1994;59:207-13. No abstract available.

PMID:
7587071
40.

An ameboma--lest we forget.

Viswanathan R, Paul J, Jayaraman L, Venugopal K, Natarajan R.

J Indian Med Assoc. 1986 Jan;84(1):18-20. No abstract available.

PMID:
3701083

Supplemental Content

Loading ...
Support Center